This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
What happened
With COVID-19 variants grabbing headlines worldwide, coronavirus stocks are again landing on the radar screens of investors. That, combined with a new supply agreement announced this morning, pushed Moderna‘s (NASDAQ: MRNA) stock up by 0.7% on Thursday, beating the gain of the S&P 500 index on the day.
So what
Moderna is greatly expanding its arrangement with Taiwan. The biotech company has signed on to provide 20 million doses of its mRNA-1273 coronavirus vaccine and its updated variant booster vaccine (if authorized for use) in 2022. This will quadruple the 5 million it is obligated to supply the island nation this year. As part of the new agreement, it will also provide an additional 15 million doses in 2023.
Image source: Getty Images.
Moderna did not disclose the financial terms of the expanded deal.
It’s the second expansion in Asia announced this week by the company. On Tuesday, it divulged that Japan’s Ministry of Health, Labor and Welfare and Takeda Pharmaceutical will take delivery of 50 million additional doses of the vaccine and, provisionally, the booster, in 2022. That doubles the 50 million already agreed for this year.
Now what
While Moderna frequently makes the headlines as the maker of one of only three coronavirus vaccines authorized for use in the US, mRNA-1273 has the green light in many other jurisdictions around the world, too. The resurgence of COVID-19 isn’t only a US problem, it’s a global issue; therefore, the company will remain on the front lines of the fight as long as it rages.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
The post Why Moderna Topped the Market on Thursday appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of May 24th 2021
More reading
- Here’s why Moderna stock soared 125% during the first 6 months of 2021
- Does This Shocking CDC Statement Mean Trouble for Pfizer and Moderna?
- With COVID-19 variant threats rising, why are vaccine stocks falling?
- Why Moderna shares surged 27% in June
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
from The Motley Fool Australia https://ift.tt/3xZlS3x
Leave a Reply